These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
653 related articles for article (PubMed ID: 18435430)
21. Rare diseases and orphan drugs. Taruscio D; Capozzoli F; Frank C Ann Ist Super Sanita; 2011; 47(1):83-93. PubMed ID: 21430345 [TBL] [Abstract][Full Text] [Related]
22. [European ordinance on orphan drugs: changes and threats]. Linthorst GE; Hollak CE Ned Tijdschr Geneeskd; 2003 Jan; 147(4):143-5. PubMed ID: 12635543 [TBL] [Abstract][Full Text] [Related]
23. Jumpstarting research into neglected diseases. Leslie M Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963 [TBL] [Abstract][Full Text] [Related]
24. R&D policy, agency costs and innovation in personalized medicine. Yin W J Health Econ; 2009 Sep; 28(5):950-62. PubMed ID: 19671480 [TBL] [Abstract][Full Text] [Related]
25. Access to orphan drugs in Europe: current and future issues. Michel M; Toumi M Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):23-9. PubMed ID: 22280193 [TBL] [Abstract][Full Text] [Related]
26. Perspectives on stimulating industrial research and development for neglected infectious diseases. Webber D; Kremer M Bull World Health Organ; 2001; 79(8):735-41. PubMed ID: 11545330 [TBL] [Abstract][Full Text] [Related]
27. EU orphan regulation--ten years of application. Michaux G Food Drug Law J; 2010; 65(4):639-69, i-ii. PubMed ID: 24479246 [TBL] [Abstract][Full Text] [Related]
28. Drug development for orphan diseases in the context of personalized medicine. Brewer GJ Transl Res; 2009 Dec; 154(6):314-22. PubMed ID: 19931198 [TBL] [Abstract][Full Text] [Related]
29. Legal and regulatory aspects of orphan drugs. Shani S; Yahalom Z Pediatr Endocrinol Rev; 2013 Nov; 11 Suppl 1():110-5. PubMed ID: 24380129 [TBL] [Abstract][Full Text] [Related]
31. Public-private partnership: from there to here. Croft SL Trans R Soc Trop Med Hyg; 2005 Oct; 99 Suppl 1():S9-14. PubMed ID: 16087204 [TBL] [Abstract][Full Text] [Related]
32. [Orphan drugs: availability, reliability and reimbursement]. Kreeftmeijer-Vegter AR; van Veldhuizen CK; de Vries PJ Ned Tijdschr Geneeskd; 2012; 156(17):A4252. PubMed ID: 22531041 [TBL] [Abstract][Full Text] [Related]
33. A new era of hope for the world's most neglected diseases. The PLoS Med; 2005 Sep; 2(9):e323. PubMed ID: 16138790 [TBL] [Abstract][Full Text] [Related]
35. Orphan drugs and orphan tests in the USA. Thoene JG Community Genet; 2004; 7(4):169-72. PubMed ID: 15692190 [No Abstract] [Full Text] [Related]
36. [The legal regulation of life cycle of orphan pharmaceuticals]. Gildeyeva GN; Kartavtsova TV Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2014; (3):37-42. PubMed ID: 25219041 [TBL] [Abstract][Full Text] [Related]
37. Orphan drugs: the regulatory environment. Franco P Drug Discov Today; 2013 Feb; 18(3-4):163-72. PubMed ID: 22981668 [TBL] [Abstract][Full Text] [Related]
38. History of Orphan Drug Regulation-United States and Beyond. Haffner ME Clin Pharmacol Ther; 2016 Oct; 100(4):342-3. PubMed ID: 27392514 [TBL] [Abstract][Full Text] [Related]
40. New non-profit organization will support research to combat neglected diseases. Walgate R Bull World Health Organ; 2002; 80(10):842-3. PubMed ID: 12471410 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]